Month: October 2021

Effect of pyrethroids on B. bassiana dry biomass content and metabolic activity After 36 h of incubation, statistically significant (P < 0.01) changes in biomass dry weight were observed in the B. bassiana samples supplemented with pyrethroids at the concentrations of 50 and 100 mg L−1 (Supplementary Table S1). However, after 48 h of incubation, statistically significant changes were noted
0 Comments
Takeda has exercised an option first penned in 2017 to acquire U.K. T-cell therapy expert GammaDelta Therapeutics. The Japanese pharma has also resolved an FDA warning letter regarding its Hikari, Japan, plant, which will make Novavax’s COVID-19 vaccine for the country. Fujifilm Diosynth has started construction of a massive biologics plant in North Carolina, with a
0 Comments
Novartis have announced that the investigational oral therapy, iptacopan (LNP023), has been awarded an Innovation Passport for the treatment of C3 glomerulopathy (C3G) by the MHRA, NICE, and the SMC. It is currently being investigated in a number of complement-driven renal diseases(CDRDs), alongside one haematological disorder, for patients with high unmet need. The Innovation Passport
0 Comments
Among the neurotransmitters in the brain, dopamine has gained an almost mythical status. Decades of research have established its contribution to several seemingly unrelated brain functions including learning, motivation, and movement, raising the question of how a single neurotransmitter can play so many different roles. Among the neurotransmitters in the brain, dopamine has gained an
0 Comments
Study of RUNX2 locus in modern and ancient humans The sequences of the RUNX2 locus (Chr6:45,318,000–45,670,000 hg38, for a total of 352.000 bases) have been aligned in AMH and ancient species’ (Neandertal and Denisovan) genomes to map the changes occurred during recent evolution. We have identified 459 and 470 changes (including nucleotide substitutions, indels, and
0 Comments
Pacira BioSciences wants women to lead the conversation surrounding managing  their pain—even if it’s a little embarrassing. In mid-October, the biopharma hosted “The Future is Female” virtual panel discussing the usually hushed-toned topics of pelvis and sexual pain, intimacy after cancer and postpartum recovery. Moderator Beth Battaglino, CEO of Healthy Women, an educational health website
0 Comments
Takeda has exercised its option to acquire London-based GammaDelta Therapeutics for a pre-negotiated upfront and future potential milestone payment. GammaDelta is focused on research into gamma delta T cells for potential use in immunotherapy, primarily addressing solid tumours. Following its acquisition of the firm, Takeda will gain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ)
0 Comments
Today, the Centers for Disease Control and Prevention (CDC) is issuing Orders to implement the new travel policy announced by the Biden administration to safely resume global travel to the United States while protecting the health and safety of American communities from COVID-19. These Orders put in place a stringent and consistent global international travel
0 Comments
Two new studies revealed that anti-PD-1 immunotherapy given before surgery was safe and effective for patients with oral-cavity squamous cell carcinoma (OCSCC) and identified potential molecular biomarkers in the blood and tumors of patients that would show how likely it is that someone would respond to immunotherapy. Two new studies revealed that anti-PD-1 immunotherapy given
0 Comments
As gene therapies become increasingly successful, companies are in a competitive race to deliver manufacturing technologies that can streamline large-scale production at reduced costs and faster turnaround times. However, plasmids, the building blocks of viral vectors, remain a bottleneck in gene therapy manufacturing. Two companies have united to provide exciting alternatives. With over 2,400 gene
0 Comments
Competing interests AS: CONSULTANT: for Novartis, Allergan, Bayer and Intas. BDK: CLINICAL RESEARCH: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; CONSULTANT: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. FB: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La
0 Comments